Events

Valneva will present a poster on the cost-effectiveness of IXCHIQ® vaccination in Puerto Rico.

Valneva will hold a presentation on the pivotal Phase 3 six-month safety and immunogenicity data of its single-dose chikungunya vaccine in adolescents in Brazil on November 16, 2024, at 11:15 am Central Daylight Time (CDT). The Company will also display four posters: “Chikungunya: Ongoing Dose-Response, Safety, and Immunogenicity Phase 2 Trial of Single-dose Live-attenuated Vaccine (VLA1553) in Children aged 1 to 11 years”, “Modelling of 5 Year Antibody Persistence after Vaccination with Live Attenuated Chikungunya Vaccine VLA1553 (IXCHIQ®)”, “The Global Health Burden of Chikungunya from 2011 to 2020: A Model-Driven Analysis on the Impact of an Emerging Vector-Borne Disease” and “Predicting Chikungunya in Miami: Outbreak Impact and Effectiveness of Vaccine Intervention with IXCHIQ”.

Fireside chat and investor meetings

The meeting will be conducted in a hybrid way – in person and webcast. Please register.

The event will focus on Valneva’s robust pipeline of potentially first-, only-, or best-in-class vaccine candidates addressing major unmet medical needs in infectious disease: Lyme disease (Phase 3, led by Pfizer), Shigella (Phase 2), and Zika (Phase 1). It will also highlight Valneva’s growing portfolio of revenue-generating vaccines, including the launch of the world’s first and only approved vaccine against chikungunya virus.

Speakers from Company management will include Thomas Lingelbach, Chief Executive Officer and member of the Board of Directors, as well as other members of the Management Team.

A live question and answer session will follow the formal presentation.